Cancer Top Therapeutic Area in Biosimilars Development

Among major therapeutic segments, cancer-related biosimilars will be the market leader, says RNCOS' latest research report.

Noida, India (prHWY.com) April 2, 2012 - Biosimilars are gaining acceptance and popularity across the globe, and expected to attain further momentum in the coming years due to the patent expirations of key biologics. According to a new research report by RNCOS, cancer is one of the most deadly diseases worldwide, and drugs specific to treating oncology will have the greatest demand. Even in the biosimilars industry, among various therapeutic segments, biosimilars curing cancer will grow the fastest. Cost benefits over expensive branded biologics will be the main factor in their greater market penetration. With several cancer biosimilars in the pipeline, their market share is expected to increase significantly.

The 140-page report, "Global Biosimilars Market Forecast to 2015", states that biologics have gained significant momentum in the recent years and have been used in a wide number of diseases. But, the generic version of biologics, biosimilar, offers cost advantage, which is driving the biosimilars market worldwide. Particularly, second generation biosimilars are expected to open up great avenues in the industry. In the next decade, patent expiry of key blockbuster drugs, such as Avastin and Rituxan, along with other prominent factors will drive the global biosimilars market, which is anticipated to expand at an impressive double digit rate from 2010 to 2015.

The study provides an extensive research and in-depth analysis of the current size and future outlook of the global biosimilars market. It includes the market analysis, key market segments and geographical segmentation. Various types of biosimilars, such as erythropoietin, human growth hormone, G-CSF, monoclonal antibody, human insulin and interferons have been analyzed in depth in the report. The biosimilars industry is highly varied in regulated and unregulated markets, and some of the key geographies in this regard have been analyzed. The study also analyzes the opportunities for companies in the market, in terms of key sub-segments and therapeutic areas. Overall, the research report aims at providing a balanced outlook on the market potentials.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM379.htm

Some of our Related Reports are:

- Cancer Monoclonal Antibodies Market to 2015 (http://www.rncos.com/Report/IM375.htm)
- US Biotech Market Analysis (http://www.rncos.com/Report/IM0300.htm)
- Global miRNA Market Outlook (http://www.rncos.com/Report/IM286.htm)
- Global HIV Therapeutics Market Analysis (http://www.rncos.com/Report/IM361.htm)
- Booming Biotech Market in India (http://www.rncos.com/Report/IM110.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Tag Words: global biosimilars market

Categories: Biotech

Press Release Contact
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707

Link To This Press Release:

URL HTML Code